912-60-7

912-60-7 structure

Name: Noscapine hydrochloride
Chemical Name: Noscapine hydrochloride,(3S)-6,7-Dimethoxy-3-[(5R)-5,6,7,8-tetrahydro-4-methoxy-6-methyl-1,3-dioxolo[4,5-g]isoquinolin-5-yl]-1(3H)-isobenzofuranonehydrochloride
CAS Number: 912-60-7
Molecular Formula: C₂₂H₂₄ClNO₇
Molecular Weight: 449.882
Catalog: API Respiratory medication Antitussive
Create Date: 2018-06-27 15:52:44
Modify Date: 2024-01-03 00:16:42
Noscapine hydrochloride ((S,R)-Noscapine hydrochloride) is an orally active phthalideisoquinoline alkaloid with potent antitussive. Noscapine hydrochloride exerts its antitussive effects by activating sigma opioid receptors and is a non-competitive Bradykinin inhibitor. Noscapine hydrochloride disrupts microtubule dynamics, induces mitotic arrest and apoptosis. Noscapine hydrochloride possesses anticancer, neuroprotective, anti-inflammatory activities, and can crosse the blood-brain barrier[1][2][3][4][5].

Name	Noscapine hydrochloride,(3S)-6,7-Dimethoxy-3-[(5R)-5,6,7,8-tetrahydro-4-methoxy-6-methyl-1,3-dioxolo[4,5-g]isoquinolin-5-yl]-1(3H)-isobenzofuranonehydrochloride
Synonyms	Narcosine hydrochloride longatinhydrochloride EINECS 213-014-9 Terbenol hydrochloride Capval NOSCAPINE BASE / HCL MFCD00082546 nectadonhydrochloride Nectadon hydrochloride Opian hydrochloride Vadebex hydrochloride lyobexhydrochloride coscopinhydrochloride Coscopin hydrochloride 1,3-Dioxolo[4,5-g]isoquinolinium, 5-[(1S)-1,3-dihydro-4,5-dimethoxy-3-oxo-1-isobenzofuranyl]-5,6,7,8-tetrahydro-4-methoxy-6-methyl-, chloride, (5R)- (1:1) Narcompren hydrochloride opianhydrochloride capvalhydrochloride Opianine hydrochloride vadebexhydrochloride (5R)-5-[(1S)-4,5-Dimethoxy-3-oxo-1,3-dihydro-2-benzofuran-1-yl]-4-methoxy-6-methyl-5,6,7,8-tetrahydro[1,3]dioxolo[4,5-g]isoquinolin-6-ium chloride Methoxyhydrastine hydrochloride Noscapine HCl Noscapine hydrochloride Narcotine hydrochloride

Description	Noscapine hydrochloride ((S,R)-Noscapine hydrochloride) is an orally active phthalideisoquinoline alkaloid with potent antitussive. Noscapine hydrochloride exerts its antitussive effects by activating sigma opioid receptors and is a non-competitive Bradykinin inhibitor. Noscapine hydrochloride disrupts microtubule dynamics, induces mitotic arrest and apoptosis. Noscapine hydrochloride possesses anticancer, neuroprotective, anti-inflammatory activities, and can crosse the blood-brain barrier[1][2][3][4][5].
Related Catalog	Signaling Pathways >> Apoptosis >> Apoptosis Research Areas >> Cancer Signaling Pathways >> GPCR/G Protein >> Opioid Receptor Research Areas >> Inflammation/Immunology Signaling Pathways >> Neuronal Signaling >> Opioid Receptor Research Areas >> Neurological Disease
Target	Sigma opioid receptors[4]Bradykinin[5]Apoptosis[1]
In Vitro	Noscapine (0-1000 μM; 0-96 hours; rat C6 glioma cells) treatment inhibits cell viability of rat C6 glioma in vitro in a dose- and time-dependent manner. Noscapine inhibits the viability of rat C6 glioma cells with an IC50 of 250 μM at 72 hours[1]. Noscapine exposure causes abnormal S-phase reentry, increases mitotic arrest and results in excessive DNA accumulation[1]. Cylindromatosis increases the ability of noscapine to induce mitotic arrest and apoptosis. Cylindromatosis enhances the effect of noscapine on microtubule polymerization and promotes noscapine binding to microtubules[2]. Cell Proliferation Assay[1] Cell Line: Rat C6 glioma cells Concentration: 0 μM, 0.1 μM, 1 μM, 2 μM, 10 μM, 50 μM, 100 μM, 1000 μM Incubation Time: 0 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours Result: Inhibited cell viability of rat C6 glioma in vitro in a dose- and time-dependent manner.
In Vivo	Noscapine (300 mg/kg; oral gavage; daily; for 15 days; athymic female mice) treatment reduces tumor growth in mice[1]. Animal Model: Athymic female mice (nu/nu) (8-week-old) injected with rat C6 glioma cells[1] Dosage: 300 mg/kg Administration: Oral gavage; daily; for 15 days Result: Revealed a significant reduction of tumor volume.
References	[1]. Jaren W Landen, et al. Noscapine Crosses the Blood-Brain Barrier and Inhibits Glioblastoma Growth. Clin Cancer Res. 2004 Aug 1;10(15):5187-201. [2]. Yang Y, et al. CYLD Regulates Noscapine Activity in Acute Lymphoblastic Leukemia via a Microtubule-Dependent Mechanism. Theranostics. 2015 Mar 2;5(7):656-666. [3]. Vartika Tomar, et al. Noscapine and Its Analogs as Chemotherapeutic Agent: Current Updates. Curr Top Med Chem. 2017;17(2):174-188. [4]. Bianca Lokhorst, et al. Interaction of OTC Drug Noscapine and Acenocoumarol and Phenprocoumon. Br J Clin Pharmacol. 2019 May;85(5):1041-1043. [5]. S A Ebrahimi, et al. Interaction of Noscapine With the Bradykinin Mediation of the Cough Response. Acta Physiol Hung. 2003;90(2):147-55.

Density	1.332g/cm3
Boiling Point	565.3ºC at 760mmHg
Melting Point	221-223ºC
Molecular Formula	C₂₂H₂₄ClNO₇
Molecular Weight	449.882
Flash Point	295.7ºC
Exact Mass	449.124115
PSA	75.69000
LogP	3.62170
Storage condition	2-8°C
Water Solubility	Freely soluble in water and in ethanol (96 per cent). Aqueous solutions are slightly acid; the base may be precipitated when the solutions are allowed to stand.

CHEMICAL IDENTIFICATION

RTECS NUMBER :: NP7225000

CHEMICAL NAME :: 1(3H)Isobenzofuranone, 6,7-dimethoxy-3-(5,6,7,8-tetrahydro-4-methoxy-6-methy l-1,3-dioxolo (4,5-g)isoquinolin-5-yl)-, hydrochloride, (S-(R*,S*))-

CAS REGISTRY NUMBER :: 912-60-7

LAST UPDATED :: 199009

DATA ITEMS CITED :: 7

MOLECULAR FORMULA :: C22-H23-N-O7.Cl-H

MOLECULAR WEIGHT :: 449.92

WISWESSER LINE NOTATION :: T C566 DO FO KN EH&&TJ HO1 K1 J- DT56 BVO DHJ HO1 IO1 &GH

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 853 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 581 mg/kg

TOXIC EFFECTS :: Behavioral - somnolence (general depressed activity) Behavioral - convulsions or effect on seizure threshold Behavioral - ataxia

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 700 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: 52 mg/kg

TOXIC EFFECTS :: Behavioral - convulsions or effect on seizure threshold Lungs, Thorax, or Respiration - dyspnea Kidney, Ureter, Bladder - urine volume increased

TYPE OF TEST :: LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - guinea pig

DOSE/DURATION :: 83 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

MUTATION DATA

TYPE OF TEST :: Cytogenetic analysis

TEST SYSTEM :: Rodent - hamster Lung

DOSE/DURATION :: 60 mg/L

REFERENCE :: GMCRDC Gann Monograph on Cancer Research. (Plenum Pub. Corp., 233 Spring St., New York, NY 10013) No. 11- 1971- Volume(issue)/page/year: 27,95,1981

Symbol	GHS07
Signal Word	Warning
Hazard Statements	H302
Personal Protective Equipment	dust mask type N95 (US);Eyeshields;Gloves
Hazard Codes	Xi:Irritant;
Risk Phrases	R22
Safety Phrases	S36
RIDADR	UN 1544
WGK Germany	3
RTECS	NP7225000
Packaging Group	III
Hazard Class	6.1(b)

Precursor 0
DownStream 4
4593-97-9 569-31-3 550-10-7 19641-12-4

912-60-7	128-62-1
6138-79-0	143851-98-3
1406-14-0	929-73-7
127228-87-9	1334385-87-3
56-99-5	1406-02-6
1704516-62-0	1158522-08-7
1775453-84-3	1775554-51-2
940364-43-2	134104-43-1
131615-57-1	6906-52-1
2034206-76-1	930439-75-1